Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest Airway Clearance System. Products are sold in U.S. home-care and institutional markets and internationally through direct sales and distributors. This unaudited report covers the three months ended September 30, 2012, the first quarter of fiscal 2013, compared with the three months ended September 30, 2011.
Key Financial Metrics
| Metric | Q1 FY2013 | Q1 FY2012 | Change |
|---|---|---|---|
| Net revenue | $4.031 million | $5.379 million | Down 25.1% |
| Gross profit | $2.821 million | $4.069 million | Down 30.7% |
| Gross margin | 70.0% | 75.6% | Down 5.6 percentage points |
| Operating income (loss) | $(96,000) | $452,000 | Declined $549,000 |
| Net income (loss) | $(71,000) | $246,000 | Declined $317,000 |
| Basic and diluted EPS | $(0.01) | $0.03 | Declined $0.04 |
| Cash flow from operations | $114,000 | $(823,000) | Improved $937,000 |
| Capital expenditures and patent costs | $224,000 | $237,000 | Down $13,000 |
Home-care revenue was $3.574 million, down 30.4%; international revenue was $109,000, up 194.6%; and government/institutional revenue was $348,000, up 65.7%. The company attributed the home-care decline primarily to fewer referrals and a smaller, less experienced clinical sales force. Lower gross margin reflected the mix of referrals, including lower reimbursement diagnoses and insurance programs.
Operating expenses were $2.917 million, down 19.3%. SG&A declined 17.2% to $2.816 million, while research and development declined 53.5% to $101,000. The company reported a $62,000 income tax benefit versus $163,000 of tax expense in the prior-year quarter; the effective tax rates were 46.6% and 39.9%, respectively.
Balance Sheet, Debt and Liquidity
- Cash and cash equivalents were $1.483 million at September 30, 2012, compared with $1.702 million at June 30, 2012.
- Accounts receivable were $10.415 million, inventories were $2.305 million and total current assets were $15.728 million.
- Total liabilities were $5.390 million and total equity was $15.051 million.
- Total debt outstanding under the U.S. Bank credit facility was approximately $3.257 million, consisting of $1.768 million on the revolving line and approximately $1.489 million of term debt.
- Net unused availability under the revolving line was approximately $2.652 million. The $6.0 million revolving facility expires December 31, 2013, if not renewed.
- The company stated that cash, operating cash flow and available borrowings are expected to provide adequate liquidity for the next year, but additional financing may be required and may not be available on favorable terms.
Material Changes Versus the Prior Comparable Period
- Revenue fell $1.348 million, primarily because home-care referrals declined. Average clinical area managers decreased from 24 to 21, and managers with more than one year of experience decreased from 17 to 14.
- Gross margin contracted from 75.6% to 70.0%, although management did not view the quarter's margin as indicative of a long-term decline.
- Expense reductions partially offset the revenue decline, including lower commissions, management compensation, travel, marketing, professional fees and outside research-and-development costs.
- Operating results shifted from profit to loss, while operating cash flow improved because of lower expenses, improved collections and reductions in accounts receivable and inventory.
- Related-party research-and-development services ended after June 30, 2012; no related-party R&D expense was recorded in the quarter versus approximately $90,000 in the prior-year quarter.
Outlook, Risks, Contingencies and Unusual Items
Management hired a new Director of Sales, brought strategic marketing responsibility in-house, realigned sales territories and implemented a new compensation plan after the quarter. Management expects these actions, additional clinical area managers and expense efficiencies to support future sales growth, profitability and improved margins. It expects research and development spending to approximate 5.0% of sales for the foreseeable future.
International sales may be affected by distributor-purchase timing, global economic conditions and the European sovereign debt situation. Principal risks include reimbursement changes involving Medicare, Medicaid and private insurers; healthcare-law and regulatory changes; competition; sales-force execution; intellectual-property protection and litigation; financing availability; and general economic conditions.
The company violated certain financial covenants under its credit facility during the quarter. U.S. Bank waived the resulting event of default as of September 30, 2012. Term Loan B, with approximately $1.0 million originally outstanding, had a maturity date of December 9, 2012. The company reported no material undisclosed litigation and no off-balance-sheet arrangements. Management concluded that disclosure controls were effective and reported no material changes in internal control over financial reporting.
Investor Verification Items
- Verify the sustainability of home-care referral volumes and the effectiveness of the revised sales territories, compensation plan and sales-force expansion.
- Monitor gross margin and reimbursement mix to determine whether the 70.0% quarterly margin was temporary or structural.
- Review compliance with credit-facility covenants, the September 2012 waiver and the refinancing or repayment of debt maturing in December 2012.
- Reconcile reported borrowing availability with eligible receivables and the facility’s borrowing-base restrictions.
- Assess liquidity needs for sales-force hiring, capital expenditures, research and development and working capital.
- Track warranty-reserve adequacy, reimbursement exposure, regulatory requirements and potential intellectual-property claims.